Výsledky vyhľadávania - "Nivolumab/therapeutic use [MeSH]"

FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)

Autori: Isfort, Susanne Bubnoff, Nikolas von Al-Ali, Haifa Kathrin a ďalší

Zdroj: Ann Hematol

Predmety: Male, 0301 basic medicine, Pyrrolidines, Benzenesulfonamides, 03 medical and health sciences, Clinical Trials, Phase II as Topic, Germany, Antineoplastic Combined Chemotherapy Protocols, Nitriles, Humans, Janus Kinase Inhibitors, Aged, Checkpoint-inhibitor, Aged [MeSH], Fedratinib, Pyrazoles/therapeutic use [MeSH], Myeloproliferative Disorders/drug therapy [MeSH], Sulfonamides/therapeutic use [MeSH], Primary Myelofibrosis/drug therapy [MeSH], Male [MeSH], Benzenesulfonamides [MeSH], Myelofibrosis (MF), Pyrrolidines/therapeutic use [MeSH], Female [MeSH], Janus Kinase 2/antagonists, Janus Kinase 2/genetics [MeSH], Nitriles/therapeutic use [MeSH], Humans [MeSH], Janus Kinase Inhibitors/therapeutic use [MeSH], Middle Aged [MeSH], Sulfonamides/administration, Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Nivolumab, Pyrimidines/therapeutic use [MeSH], Myeloproliferative Neoplasms (MPN), Research, Germany [MeSH], Nivolumab/administration, Nivolumab/therapeutic use [MeSH], Disease modification, Sulfonamides, 0303 health sciences, Myeloproliferative Disorders, Middle Aged, Janus Kinase 2, Pyrimidines, Primary Myelofibrosis, Pyrazoles, Female

Popis súboru: pdf

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38967662
https://repository.publisso.de/resource/frl:6518685

Quality of life under treatment with the immune checkpoint inhibitors ipilimumab and nivolumab in melanoma patients. Real-world data from a prospective observational study at the Skin Cancer Center Kiel

Autori: Grote, Carolin Bohne, Ann-Sophie Blome, Christine a ďalší

Zdroj: J Cancer Res Clin Oncol

Predmety: Male, Adult, Aged, 80 and over, Skin Neoplasms, Research, Surveys and Questionnaires [MeSH], Aged, 80 and over [MeSH], Melanoma, Aged [MeSH], Skin Neoplasms/drug therapy [MeSH], Nivolumab/adverse effects [MeSH], Ipilimumab/administration, Male [MeSH], Immune Checkpoint Inhibitors/adverse effects [MeSH], Melanoma/pathology [MeSH], Quality of Life [MeSH], Skin Neoplasms/immunology [MeSH], Melanoma/drug therapy [MeSH], HrQoL, Female [MeSH], Adult [MeSH], Humans [MeSH], Prospective Studies [MeSH], Ipilimumab/adverse effects [MeSH], Middle Aged [MeSH], Skin Neoplasms/pathology [MeSH], Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], ICI, Immune Checkpoint Inhibitors/therapeutic use [MeSH], Distress thermometer, Antineoplastic Combined Chemotherapy Protocols/adverse effects [MeSH], Ipilimumab/therapeutic use [MeSH], IBDQ-D, SF-36, Nivolumab/administration, Nivolumab/therapeutic use [MeSH], Middle Aged, Ipilimumab, Nivolumab, Surveys and Questionnaires, Antineoplastic Combined Chemotherapy Protocols, Quality of Life, Humans, Female, Prospective Studies, Immune Checkpoint Inhibitors, Aged

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39387946
https://repository.publisso.de/resource/frl:6497979

Efficacy of adjuvant immune checkpoint inhibitors pembrolizumab or nivolumab in melanoma patients ≥ 75 years: results of a real-world cohort including 456 patients

Autori: A. Gawaz I. Wolff L. Nanz a ďalší

Zdroj: Cancer Immunol Immunother

Predmety: Male, Aged, 80 and over, Skin Neoplasms, Research, Aged, 80 and over [MeSH], Melanoma, ≥ 75 years, Aged [MeSH], Skin Neoplasms/drug therapy [MeSH], Nivolumab/adverse effects [MeSH], Male [MeSH], Immune Checkpoint Inhibitors/adverse effects [MeSH], Chemotherapy, Adjuvant/methods [MeSH], Elderly patients, Melanoma/drug therapy [MeSH], Female [MeSH], Humans [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Melanoma/mortality [MeSH], Immune Checkpoint Inhibitors/therapeutic use [MeSH], Adjuvant therapy, Melanoma/immunology [MeSH], Antibodies, Monoclonal, Humanized/therapeutic use [MeSH], Immune checkpoint inhibitor, Skin Neoplasms/mortality [MeSH], Nivolumab/therapeutic use [MeSH], Antibodies, Monoclonal, Humanized/adverse effects [MeSH], Middle Aged, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Nivolumab, 0302 clinical medicine, Chemotherapy, Adjuvant, Humans, Female, Immune Checkpoint Inhibitors, Aged, Retrospective Studies

Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38969911
https://repository.publisso.de/resource/frl:6524688

Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma

Autori: Maria Garcia-Marquez Andreas Engert Sarah Reinke a ďalší

Zdroj: Leukemia

Predmety: EXPRESSION, Male, 0301 basic medicine, BLOCKADE, T-Lymphocytes, MICROENVIRONMENT, ANTIGENS, Article, MECHANISMS, 03 medical and health sciences, Antigens, Neoplasm, Humans, PEMBROLIZUMAB, Immune Checkpoint Inhibitors, ddc:610, 0303 health sciences, Immunity, NIVOLUMAB, Hodgkin Disease, 3. Good health, Female [MeSH], Immunosurveillance, Hodgkin Disease/drug therapy [MeSH], T-Lymphocytes/drug effects [MeSH], T-Lymphocytes/immunology [MeSH], Humans [MeSH], Lymphocytes, Hodgkin Disease/immunology [MeSH], Immune Checkpoint Inhibitors/therapeutic use [MeSH], Antigens, Neoplasm/immunology [MeSH], Male [MeSH], Immunotherapy, Nivolumab/therapeutic use [MeSH], Hodgkin lymphoma, Immunity/drug effects [MeSH], RECEPTORS, Nivolumab, T-CELLS, PHASE-II, Female

Popis súboru: application/pdf

Prístupová URL adresa: https://www.nature.com/articles/s41375-021-01421-z.pdf
https://pubmed.ncbi.nlm.nih.gov/34584203
https://research.rug.nl/en/publications/c9d33d29-a07b-42ca-b2ad-1db7b644c001
https://doi.org/10.1038/s41375-021-01421-z
https://hdl.handle.net/11370/c9d33d29-a07b-42ca-b2ad-1db7b644c001
https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2Fc9d33d29-a07b-42ca-b2ad-1db7b644c001
https://www.nature.com/articles/s41375-021-01421-z
https://research.rug.nl/nl/publications/reverted-exhaustion-phenotype-of-circulating-lymphocytes-as-immun
https://facultyopinions.com/prime/740896206
https://pubmed.ncbi.nlm.nih.gov/34584203/
https://www.nature.com/articles/s41375-021-01421-z.pdf
https://repository.publisso.de/resource/frl:6443788
https://opus.bibliothek.uni-wuerzburg.de/files/34623/MariaA.GarciaMarquez.pdf
https://doi.org/10.1038/s41375-021-01421-z
https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/34623
https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-346237

Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition

Autori: Julian Taugner Lukas Käsmann Monika Karin a ďalší

Zdroj: Invest New Drugs

Predmety: Adult, Male, Lung Neoplasms, Age Factors [MeSH], Aged [MeSH], Antibodies, Monoclonal/therapeutic use [MeSH], Nivolumab/adverse effects [MeSH], Neoplasm Staging [MeSH], Male [MeSH], Antibodies, Monoclonal/administration, Immune Checkpoint Inhibitors/adverse effects [MeSH], Immune Checkpoint Inhibitors/administration, Chemoradiotherapy/adverse effects [MeSH], Sex Factors [MeSH], Short Report, Carcinoma, Non-Small-Cell Lung/pathology [MeSH], Antineoplastic Agents, Immunological/adverse effects [MeSH], Female [MeSH], Lung Neoplasms/therapy [MeSH], Adult [MeSH], Humans [MeSH], Prospective Studies [MeSH], Tumor volume, Chemoradiotherapy/methods [MeSH], Survival Analysis [MeSH], Checkpoint inhibition, Middle Aged [MeSH], Prediction, Immune Checkpoint Inhibitors/therapeutic use [MeSH], Chemoradiotherapy, Non-small cell lung cancer, Antineoplastic Agents, Immunological/therapeutic use [MeSH], Lung Neoplasms/pathology [MeSH], Nivolumab/administration, Antineoplastic Agents, Immunological/administration, Nivolumab/therapeutic use [MeSH], Antibodies, Monoclonal/adverse effects [MeSH], Carcinoma, Non-Small-Cell Lung/drug therapy [MeSH], Carcinoma, Non-Small-Cell Lung/therapy [MeSH], Lung Neoplasms/drug therapy [MeSH], Age Factors, Antibodies, Monoclonal, Middle Aged, Survival Analysis, 3. Good health, 03 medical and health sciences, Antineoplastic Agents, Immunological, Nivolumab, Sex Factors, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Humans, Female, Prospective Studies, Immune Checkpoint Inhibitors, Aged, Neoplasm Staging

Prístupová URL adresa: https://link.springer.com/content/pdf/10.1007/s10637-021-01143-0.pdf
https://pubmed.ncbi.nlm.nih.gov/34351518
https://paperity.org/p/267064400/planning-target-volume-as-a-predictor-of-disease-progression-in-inoperable-stage-iii-non
https://pubmed.ncbi.nlm.nih.gov/34351518/
https://link.springer.com/content/pdf/10.1007/s10637-021-01143-0.pdf
https://link.springer.com/article/10.1007/s10637-021-01143-0
https://europepmc.org/article/MED/34351518
https://repository.publisso.de/resource/frl:6444959
https://epub.ub.uni-muenchen.de/90868/